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Introduction 
 
Normal vasculature 
 
The basic constituents of the walls of blood vessel are endothelial cells, smooth 
muscle cells, and extracellular matrix, including elastic elements, collagen and 
proteoglycans. 
They are arranged in concentric layers: 
• Intima (adjacent to the lumen) 
• Media 
• Adventitia (externally) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In normal arteries, the intima is composed of the lining endothelial cells with minimal 
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underlying subendothelial connective tissue. It is separated from the media by a dense 
elastic membrane called internal elastic lamina. The outer limit of the media of most 
arteries is marked by a well-defined external elastic lamina. 
In the large and medium-sized arteries, the smooth muscle cell layer of the media 
near the vessel lumen depends primarily on direct diffusion of oxygen from the vessel 
for their nutritional needs. Diffusion is facilitated by holes (fenestration) in the 
internal elastic membrane (Robins-Pathologic basis of disease, 1999) 
 
Endothelial cells 
 
Endothelial cells form a monolayer that lines the entire vascular systems (the 
endothelium). Vascular endothelium is a versatile multifunctional tissue having many 
synthetic and metabolic properties. Endothelial cells can respond to various abnormal 
stimuli by adjusting some of the constitutive function, by expressing newly acquired 
(induced) properties (Sumagin et al, 2008). The term endothelial dysfunctions are 
often used to describe several types of potentially reversible changes in the functional 
state of endothelial cells that occur in response to environmental stimuli (Selwyn AP 
et al, 1997). 
 
Vascular Smooth Muscle Cells 
 
Vascular smooth muscle cells (SMCs) are the stromal cells of the vascular wall, 
continually exposed to mechanical signals and biochemical components generated in 
the blood compartment. They are involved in all the physiological functions and the 
pathological changes taking place in the vascular wall. Owing to their contractile 
tonus, VSMCs of resistance vessels participate in the regulation of blood pressure and 
also in hypertension. VSMCs of conduit arteries respond to hypertension-induced 
increases in wall stress by an increase in cell protein synthesis (hypertrophy) and 
extracellular matrix secretion (Lacolley, 2012). 
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As the predominant cellular element of the vascular media, smooth muscle cells 
constitute an important element not only normal vascular repair, but also pathological 
such us atherosclerosis. The media is accessible to soluble plasma components, which 
are outwardly convected from the circulating blood through the vascular wall 
(Michel, 2007). Resting vascular smooth muscle cells are spindle shaped, with single, 
elongated nuclei resembling fibroblast. 
Cytoplasmatic filaments that contain actin and myosin mediate the contractile 
function of SMCs. During the healing response, smooth muscle cells undergo 
changes that resemble dedifferentiation (Bochaton-Piallat ML & Gabbiani G, 2005). 
SMCs migrating from the media to the intima lose the capacity to contract, gain the 
capacity to divide, and increase the synthesis of extracellular matrix molecules, often 
designated a shift from that contractile phenotype to the proliferative synthetic 
phenotype. Structurally, there is a decrease in the thick myosin-containing filaments 
and an increase in the amount of organelles involved with protein synthesis, such us 
rough endoplasmic reticulum and Golgi apparatus. The contractile state of vascular 
smooth muscle influences arterial blood pressure and regulates organ blood flow. The 
contractile apparatus of vascular smooth muscle is composed of thin and thick 
filaments, and that force generated between these two filaments provides the 
mechanism for cell shortening. The molecular events that initiate the interaction 
between these filaments are dependent upon the free sarcoplasmic concentration of 
activator calcium, which is regulated by the cell membrane and at subcellular sites. 
Changes in electrical activity of the cell membrane and interaction of pharmacologic 
agents with membrane receptors alter the cell, causing either a decrease or increase in 
sarcoplasmic calcium concentration and thus changing the contractile state of the 
vascular smooth muscle cell. Alterations in the cellular mechanisms that regulate 
intracellular calcium concentration may contribute  
 
Atherosclerosis 
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Atherosclerosis is a condition in which patchy deposits of fatty material develop in 
the walls of medium-sized and large arteries, leading to reduced or blocked blood 
flow. 
Atherosclerosis is caused by repeated injury to the walls of arteries. Many factors 
contribute to this injury, including high blood pressure, tobacco smoke, diabetes and 
high levels of cholesterol in the blood (Besler et al, 2008). Often, the first symptom is 
pain or cramps at times when blood flow cannot keep up with the tissues need for 
oxygen. To prevent atherosclerosis, people need to stop using tobacco, improve their 
diet, exercise regularly, and maintain control of their blood pressure and diabetes 
(Taylor DA & Zenovich AG, 2008). In the most developed countries, atherosclerosis 
is the leading cause of illness and death. 
Arteriosclerosis literarily means hardening of arteries; more accurately, however, it is 
a generic term for three patterns of vascular disease that have in common thickening 
and loss of elasticity of arterial walls: 
•The dominant patter is atherosclerosis, characterized by the formation of intimal 
fibrous plaques that often have a central core rich in lipid 
•Arteriolosclerosis: sclerosis and thickening of the walls of arterioles. Atherosclerosis 
is characterized by intimal lesion called atheromas or fibrofatty plaques that protrude 
into the lumen, and undergo a series of complication. 
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Figure (2). Atherosclerosis primarily affects elastic arteries (e.g., aorta, carotid and iliac arteries) 
and large and medium sized muscular arteries (e.g. coronary and popliteal arteries). The disease 
often begins in childhood, but symptoms are not usually evident until middle age or later when the 
arterial lesions precipitate organ injury (Milei, 2003). 
 
Symptomatic atherosclerotic disease is most often localized to arteries supplying the 
heart, brain, kidneys, lower extremities, and small intestine. Myocardial infarction 
(heart attack), cerebral infarction (stroke), and aortic aneurysms are the major 
consequences of this disease. Thus, epidemiologic data on atherosclerosis are 
expressed largely in terms of the incidence of or the number of death caused by 
ischemic heart disease (Robins-Pathologic basis of disease, 1999). 
 
Pathogenesis of atherosclerosis 
 
The development of atherosclerosis is complicated, but the primary event seems to be 
repeated, subtle injury to the artery‘s wall through various mechanisms. These 
mechanisms include physical stresses from turbulent blood flow (such as occurs 
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where arteries branch, particularly in people who have high blood pressure) and 
inflammatory stresses involving the immune system, certain infections, or chemical 
abnormalities in the bloodstream (high cholesterol, diabetes)(Arora S & Nicholls SJ, 
2008). 
The pathogenesis of atherosclerosis has not been well defined, however, association 
of fatty degeneration and vessel stiffing was the first definition of atherosclerosis. 
Principal events of atherosclerosis are the follow: 
•The development of focal regions of chronic endothelial injury, usually subtle, with 
resultant endothelial permeability and increased leukocyte adhesion (Crowther MA, 
2005) 
•Insudation of lipoproteins into vessel wall, mainly LDL with its high cholesterol 
content and also very-low-density lipoprotein (VLDL), and modification of such 
lipoprotein by oxidation (Torzewski M & Lackner KJ, 2006) 
•Adhesion of blood monocytes (and other leukocytes) to endothelium, followed by 
migration of monocytes into the intima and their transformation into macrophages 
and foam cells (Doran AC et al, 2008) 
•Adhesion of platelets to focal areas of denudation (when present) or to adherent 
leukocytes (DiCorleto PE, 1993) 
•Release of factors from activated platelets, macrophage, or vascular cells that cause 
migration of smooth muscle cells from media in to the intima (Bochaton- Piallat ML, 
Gabbiani G, 2005) 
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Figure (3). Classification of type lesions. 
 
Classification of type lesion 
 
Type I Lesions 
Type I lesions consist of the first microscopically and chemically detectable lipid 
deposits in the intima and the cell reactions associated with such deposits. These 
lesions have been characterized in studies in which the sequence of lesions was 
deduced from examining many persons who died at different ages (Stary et al, 1994). 
 
Type II Lesions 
Type II lesions include fatty streaks, which on gross inspection may be visible as 
yellow colored streaks, patches, or spots on the intimal surface of arteries. Fatty 
streaks stain red with Sudan III4958 or Sudan IV. 
The precursors of advanced lesions are divided into three morphologically 
characteristic types. Both type II lesions and I represent small lipid deposits in the 
arterial intima, and type II includes those lesions generally referred to as fatty streaks. 
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Fatty streaks are not significantly raised and thus do not cause any disturbance in 
blood flow. They may be precursor however of the most ominous atheromatouse 
plaque (Herbert et al, 1995). 
Type III Lesions 
The designation "type III lesion" applies only to lesions that form the morphological 
and chemical bridge between type II lesions and atheromas. 
The type III lesion is also known as the intermediate lesion, the transitional lesion, 
and as preatheroma. Its characteristic histological features are microscopically visible 
(Stery et al, 1994). 
Type IV 
In type IV lesion a dense accumulation of extracellular lipid occupies an extensive 
but well-defined region of the intima. This type of extracellular lipid accumulation is 
known as the lipid core. A fibrous tissue increase is not a feature, and complications 
such as defects of the lesion surface and thrombosis are not present. The type IV 
lesion is also known as atheroma. Type IV is the first lesion considered advanced in 
this classification because of the severe intimal disorganization caused by the lipid 
core. The characteristic core appears to develop from an increase and the consequent 
confluence of the small isolated pools of extracellular lipid that characterize type III 
lesions (Stary HC, 1989). 
Type V 
Type V lesions are defined as lesions in which prominent new fibrous connective 
tissue has formed. When the new tissue is part of a lesion with a lipid core (type IV), 
this type of morphology may be referred to as fibroatheroma or type Va lesion. A 
type V lesion in which the lipid core and other parts of the lesion are calcified may be 
referred to as type Vb. A type V lesion in which a lipid core is absent and lipid in 
general is minimal may be referred to as type Vc. With these lesions, arteries are 
variously narrowed, generally more than with type IV (Herbert et al, 1995). 
Type VI 
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Type IV or V lesions with one or more of these additional features are classified as 
type VI and may also be referred to as complicated lesions. The superimposed 
features may subdivide type VI: 
 
 
 
Role of vascular smooth muscle cells in the atherosclerotic plaque development 
 
The initiation of atherosclerosis results from complex interactions of circulating 
factors and various cell types in the vessel wall, including endothelial cells, 
lymphocytes, monocytes, and smooth muscle cells (SMCs). Human autopsy studies, 
in vitro mechanistic studies, and in vivo correlative data confirm the important role 
for SMCs in the initiation of atherosclerosis (Orlandi et al, 2006). In response to the 
initial lipid injury, certain medial SMCs acquire a synthetic and proliferative 
phenotype and lose several markers of their physiological contractile function. 
14 
 
Primary cultures of SMCs recapitulate these phenotypic modifications in vitro. There 
is strong evidence that alterations in the differentiated state of SMCs play an 
important role in fibrous cap formation and in post-angioplasty restenosis. Medial 
VSMCs migrate, proliferate, produce proteoglycans with less affinity for LDLs and 
collagens in the fibrous cap in response to many stimuli, including PDGF, LPS 
(Inaba, 2009). Foam VSMCs can evolve either towards cell death, promoting intimal 
proliferation of adjacent VSMCs (Yu et al, 2011) and plaque calcification (Clarke et 
al, 2008) 
hence participating in plaque progression, or towards more complex and tissue-
integrated responses. Apoptosis and cell death are frequent biological events in the 
initial as well as in more evolved plaques (Bjorkerud et al, 1996). 
SMCs are also capable of functions typically attributed to other cell types. Like 
macrophages, SMCs can express a variety of receptors for lipid uptake and can form 
foam-like cells, thereby participating in the early accumulation of plaque lipid 
(Doran et al, 2008). Like endothelial cells, SMCs can also express a variety of 
adhesion molecules such as vascular cell adhesion molecule-1 and intercellular 
adhesion molecule-1 to which monocytes and lymphocytes can adhere and migrate 
into the vessel wall (Doran et al,2008). 
If the hypercholesterolemia (or other inciting event) persist, smooth muscle cells 
proliferation and extracellular matrix deposition in the intima continue and are the 
major processes that convert a fatty streak into a mature fibrofatty atheroma, 
accounting for the progressive growth of atherosclerotic lesion (Rosenfeld ME, 2000). 
Arterial smooth muscle cells synthesize collagen elastin and glycoproteins. Several 
growth factors have been implicated in the proliferation of SMCs: PDGF, which is 
release by platelets adherent to the focus of endothelial injury, macrophage, 
endothelial cells, smooth muscle cells; FGF; and TGF-a. SMCs proliferation is 
modulated by inhibitors, including heparin-like molecules present in endothelial cells 
and smooth muscle cells and TGF-b derived from endothelial cells or macrophages 
(Robbins- Pathologic basis of disease, 1999). 
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SMC distinct phenotype 
 
Normally, adult medial SMCs (termed “contractile”) are arranged in concentric layers 
and are filled with myofilaments and dense bodies but contain a relatively poorly 
developed Golgi apparatus and rough endoplasmatic reticulum. In contrast, SMCs 
characteristic of the intimal lesion of atheroma atherosclerosis (termed “synthetic”) 
have lost this appearance and are characterised by an abundance of rough 
endoplasmatic reticulum and sometime no evident myofilaments (Campbell GR, 
Campbell JH, 1990). During atherosclerosis progression SMCs switching from a 
contractile to a synthetic phenotype, the concept is that a predisposed SMC 
subpopulation is responsible for the production of intimal thickening (IT). This 
possibility has been raised on the basis of original work by Beneditt and Beneditt 
(Beneditt EP, Beneditt JM, 1973) who reported that human atheromatouse plaque 
have been featured of a monoclonal lesion, recently it has been demonstrate that 
human plaques are at least oligoclonal (Swarts Sm & Murry CE, 1998). The concept 
of SMC heterogeneity has been established by the description of contractile and 
synthetic phenotypes in vivo and in vitro (Thyberg J et al, 1995). 
The contractile phenotype is typical of the differentiated artery, and the synthetic one 
is typical of developing and pathologic arteries. A further step was the 
characterization in vitro of morphologically distinct SMC populations, which has 
been observed in many species, including humans (Thomas WA, 1983). 
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Figure (5). Schematic representation of atherosclerotic process 
 
Animal model of atherosclerosis 
 
Several animals have been used for the study of atherosclerosis, such as the non-
human primates, swine, mice, guinea pigs and hamsters. However there is no one 
perfect animal model that completely replicates the stages of human atherosclerosis, 
cholesterol feeding and mechanical endothelial injury are two common features 
shared by most models of atherosclerosis (Dhanya SP, Hema CG, 2008). 
It is important to note that not all animal models for atherosclerosis develop intimal 
thickening as a precursor to lesion formation. While intimal thickening is observed in 
primate and chicken models, it is not found any of the commonly used rodent models 
(Stary et al, 1992). Although several works have attempted to study atherosclerosis in 
rodent models by injuring vessels and disrupting internal elastic lamina to induced 
SMC proliferation, the plaque that results from this approach differ significantly from 
spontaneous human atherosclerosis (Doran et al, 2008). 
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However, until now, the most-studied species has been the rat. The initial description 
of SMC heterogeneity was made in the rat carotid artery injury model, wherein 2 
SMC populations were identified: a spindle-shaped phenotype, with the classic "hill-
andvalley" growth pattern, obtained from the normal media, and an epithelioid 
phenotype, in which cells grow as a monolayer and exhibit a cobblestone morphology 
at confluence, isolated from the IT 15 days after endothelial injury (Orlandi A et al, 
1994). The findings of 2 SMC distinct phenotype have been confirmed by many 
laboratories (Bochaton- Piallat ML et al, 1996; Yan ZQ, Hansson GK, 1998). 
Irrespective of the species studied, epithelioid and rhomboid phenotypes, when 
compared with spindle-shaped SMCs, have in common several features, among 
which the most relevant are (1) enhanced proliferative activity, including serum-
independent growth in some species; (2) enhanced migratory activity; (3) increased 
proteolytic activity; (4) poor level of differentiation, as defined by citoscheletal and 
contractile protein expression and (5) high sensitivity to apoptotic stimuli. In all 
species studied, epithelioid and rhomboid SMCs show a higher proliferative activity 
than do spindleshaped SMCs; however, contrary to spindle-shaped SMCs, they stop 
growing at confluence as a result of cell contact inhibition (Hao et al, 2003). 
 
Citoscheletal proteins 
 
Alpha-Smooth muscle actin 
 
Alpha-Smooth Muscle Actin (a-SMA), an isoform typical of smooth muscle cells 
(SMC) and present in high amounts in vascular SMC. 
Despite the structural similarities between different actin isoform, there is evidence 
for functional diversity. Alpha-Smooth Muscle Actin also appears during vascular 
development but, during maturation, becomes the single most abundant protein in 
adult vascular smooth muscle cells (Gabbiani et al, 1984). Likewise, a- SMA is the 
major isoform of vascular tissue, such as the aorta, while γ-smooth muscle actin 
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predominates in the gastrointestinal and genital tracts (J. Vandekerckhove & K. 
Weber; 1979). 
Stress fibers, which have been studied mainly in cultured cells, are considered to be 
contractile organelles and are associated with the generation of isometric tension 
(Wang et al, 2006). 
In smooth muscle cells, SMA comprises a very large proportion of total cell protein, 
while the content of SMA in non-muscle cells such as myofibroblasts is much lower 
(P.D. Arora and C.A. McCulloch. 1994). 
 
 Desmin 
 
Desmin is a type III intermediate filament found near the Z line in sarcomeres. It was 
first purified in 1977, the gene was characterized in 1989, and the first knock-out 
mouse was created in 1996(Costa M et al, 2004). Desmin is only expressed in 
vertebrates, however homologous proteins are found in many organisms. It is a 52kD 
protein that is a subunit of intermediate filaments in skeletal muscle tissue, smooth 
muscle tissue, and cardiac muscle tissue. 
 
Vimentin 
 
Vimentin is a member of the intermediate filament family of proteins. Intermediate 
filaments are an important structural feature of eukaryotic cells. They, along with 
microtubules and actin microfilaments, make up the cytoskeleton. Although most 
intermediate filaments are stable structures, in fibroblasts, Vimentin exists as a 
dynamic structure (Tang DD, 2008). 
 
Smooth muscle myosyn heavy chain 
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Myosin II is a major contractile protein of skeletal, cardiac and smooth muscles. It is 
composed of two heavy chains (approximately 200 kDa) and two pairs of light chains 
(approx. 20 kDa). The myosin heavy chains form a dimer consisting of two globular 
amino-terminal heads and carboxy-terminal c (-helical coiled coil tails). 
The heads bind the light chains and contain the ATP- and actin-binding sites whereas 
the tails are involved in the assembly of myosin molecules into filaments. 
Four smooth muscle specifc myosin heavy chain isoforms are known (Quevillon- 
Chéruelet al, 1999). Two isoforms (named SMB and SMA) are defined by the 
presence or the absence of an insert of seven amino acids in the N-terminal globular 
head region. 
 
 
The study of citoscheletal proteins, which are accepted as reliable differentiation 
markers, has allowed characterization of the contractile versus the synthetic 
phenotype. 
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It should be noted that when placed in culture, all SMCs tend to show a 
dedifferentiated phenotype. With this limitation, the phenotypic variation of cultured 
SMCs furnishes important information concerning the influence of many factors on 
their biologic features. α-SMA is expressed in vascular SMCs, even at early stages of 
development, and thus represents the most general marker of SMC lineage. Although 
α-SMA is permanently expressed in SMCs, it is more abundant in spindle-shaped 
SMCs than in epithelioid or rhomboid SMCs. Desmin, an intermediate filament 
protein, and SMMHC are expressed in well-differentiated SMCs are relatively well 
studied. In cultured rat SMCs, Desmin generally disappears. In larger animals, 
Desmin is maintained at a significant level of expression in spindle-shaped SMCs, 
whereas it is hardly detectable in epithelioid and rhomboid SMCs. SMMHC are 
clearly expressed more importantly in spindle-shaped SMCs than in epithelioid and 
rhomboid SMCs (Schwartz et al, 1995; Shanahan CM et al, 1998; 
Owens GK, 1998; Sartore S et al, 1999).In general, SMCs isolated from larger 
animals, including humans, are more differentiated than those isolated from rodents. 
Porcine spindle-shaped SMCs maintain appreciable expression of α-SMA, SMMHC, 
Desmin, and Smoothelin. SMMHC, calponin, h-caldesmon, and metavinculin are 
abundantly expressed in bovine spindle-shaped SMCs (Frid MG et al, 1997; Hao H 
et al, 2002). 
 
Taken together, the data obtained in different species suggest that the degree of 
differentiation of SMCs changes with the phenotype; this integrates well into a view 
that reconciles the heterogeneity of SMCs with the modulation concepts. Once 
distinct populations have been defined, the ultimate aim is to identify genes and/or 
proteins that are differentially expressed and to test whether they are involved in the 
phenotypic changes that occur in vivo. Studies on the possibility that an SMC 
phenotype can evolve into another have shown that the results depend on the species 
used. The specific phenotype of SMC observed in vitro is maintained when they are 
placed back into an in vivo environment. The evolution of the lesion in vivo appears 
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to depend on the relative replicative activity and/or susceptibility to apoptosis of 
these phenotypes. Moreover, in the rat, an agent that influences the biologic 
behaviour of epithelioid SMCs, i.e., retinoic acid, inhibits IT formation. In the pig, 
the situation is different, in that spindleshaped SMCs can modulate into rhomboid 
SMCs and, if the stimulus ceases, can return to their original phenotype, at least in 
vitro (Hao et al, 2003). 
 
Calmodulin (CaM) 
 
Calmodulin (CaM)  is an ubiquitous calcium sensor protein which, in vertebrates and 
in plants, is encoded by a multigene family exhibiting complex regulation. One of the 
most striking features of the CaM gene family is the high degree of conservation 
among family members within a species as well as across species. Strikingly, CaM 
exists as an identical protein with no amino acid substitutions in all vertebrates 
including humans, rats, chicken, frogs, and fish. In Humans there are three different 
genes coding for CaM that are 80–81% identical to each other (Fischer, 1988). CaM 
is known to regulate the activity of numerous proteins with diverse cellular functions 
including DNA synthesis and cell division (Crocker et al, 1988; Boynton et al 1980). 
Moreover, it has been documented that CaM may be also located extracellularly and, 
therefore, may have substantial functions outside cells (Ma Et al, 2000). Calmodulin 
is an intensely studied modulator and protein regulator of many catalytic reactions in 
the cell (Klee, 1982; Means et al, 1982; Carafoli et al,1987; Cohen et al, 1988). 
Interestingly, many of these reactions reveal an apparent paradox of requiring CaM in 
reactions of opposing effects. For example, CaM activates adenylyl cyclase as well as 
cyclic nucleotide phosphodiesterase. CaM, therefore, is essential in both the synthesis 
and degradation of a prominent second messenger molecule, cyclic AMP, and these 
opposing reactions must obviously be carefully controlled. CaM is assumed to be 
involved in many diseases including Parkinson, Alzheimer, and rheumatoid arthritis 
(Emilie et al, 2013). 
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Nephroblastoma overexpressed protein NOV 
 
CCN3 (also termed nephroblastoma overexpressed, NOV) belongs to the CCN 
family, which has five additional members: cystein-rich protein 61 (Cyr61), 
connective tissue growth factor (CTGF), Wnt-1-induced secreted protein (WISP)-1, 
WISP-2 and WISP-3. CCN proteins are involved in fundamental biological processes 
such as cell proliferation, attachment, migration, differentiation, wound healing, 
angiogenesis and tumorigenesis (Perbal B, 2001). 
The CCN3 protein is detectable at varying levels in the,  kidney, muscle, cartilage, 
brain, lung, ovary and heart (Joliot et al, 1992; Chevalier et al, 1998; Perbal et al, 
2001),as well as its mRNA (Fig. 7).The functions of CCN3 protein among these 
different tissues are, however, different. CCN3 was originally described as antiprolif-
erative (Joliot et al, 1992), and its expression was associated with differentiation of 
Wilms' tumor (Chevalier et al, 1998), rhabdomyosarcomas (Manara et al, 2002), 
neuroblastomas (Perbal, 2006), cartilaginous tumors (Yu et al, 2003), adrenocortical 
tumors (Doghman et al, 2007) and with inhibition of the growth and decrease in 
tumorigenicity of several tumor cell lines including glioblastoma (Gupta et al, 2001), 
choriocarcinoma (Gellhaus et al 2004) and Ewing's sarcoma (Benini et al, 2005). 
Furthermore, CCN3 expression was correlated with the increased proliferative index 
of 3T3 fibroblast (Liu et al, 1999) and tissue samples of the prostate (Maillard et al, 
2001). Although CCN3 reduced the growth rate of Ewing's sarcoma transfectants ex 
vivo, CCN3 expression was associated with poor prognosis and shown to increase 
cell motility, resulting in enhanced metastatic potential (6,12). 
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Figure (7). NOV RNA levels by microarray analysis in different human tissues. The figure is taken 
from the following link http://www.genecards.org/ and shows a study of microarray conducted in 
human tissues. The bars are representative of quantity of NOV in the different districts.  
 
 All CCN proteins have a similar modular structure, which consists of an 
amino-terminal secretory peptide followed by four conserved domains with sequence 
homologies to insulin-like growth factor-binding proteins, the von Willebrand factor 
C (VWC) domain, thrombospondin type 1 repeat (TSR) and a carboxy-terminal 
domain that contains a cysteine-knot motif (BOX 1). A non-conserved, protease-
sensitive central hinge region bisects the proteins into two halves that bind to distinct 
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cell-surface receptors. The expression of CCN proteins is exquisitely regulated on 
transcriptional, post-transcriptional and translational levels in response to changes in 
environmental stimuli, including those encountered during tissue repair (BOX 1; FIG. 
8). 
 
 
Figure (8). Representation of NOV gene. 
CCN proteins have been implicated in several vascular pathologies, including 
atherosclerosis, restenosis, thrombosis and hypertension. CCN3 expression is 
substantially reduced following balloon injury. CCN3 inhibits smooth muscle cell 
proliferation in culture, and CCN3-null mice suffer from enhanced neointimal 
thickening when challenged with vascular injury, which indicates that CCN3 inhibits 
neointimal hyperplasia (Shimoyama et al, 2010). Likewise, CCN5 inhibits vascular 
smooth muscle cell proliferation and motility, and its expression is substantially 
reduced in arteries after balloon-induced injury (Lake et al, 2003). 
Targeting strategies, such as the use of siRNA or antisense oligonucleotides to 
downregulate the expression of genes encoding specific CCN proteins, have been 
successful in animal model (Brigstock, 2009). The use of synthetic peptides as 
targeting agents for CCN proteins has not been explored in as much detail but 
nevertheless has some therapeutic potential. 
 
Ectonucleotide pyrophosphatase/phosphodiesterase 2 ENPP2 
 
Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) also known as 
Autotaxin, is a secreted lysophospholipase D that generates the lipid mediator 
lysophosphatidic acid (LPA), which in turn activates G protein-coupled receptors to 
evoke various cellular responses. ATX is essential for normal development, is 
implicated in various physiological processes, and is also associated with 
pathological conditions such as cancer, pain and fibrosis. Despite its importance, the 
IGFBP VWC TSR C-terminal  
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molecular mechanism of ENPP2-catalyzed LPA production has long been elusive 
(Nishimasu et al, 2012). As many other biological active lipids, LPA is an autacoid: it 
is formed locally on demand, and it acts locally near its site of synthesis. LPA has a 
plethora of biological activities on blood cells (platelets, monocytes) and cells of the 
vessel wall (endothelial cells, smooth muscle cells, macrophages) that are all key 
players in atherosclerotic and atherothrombotic processes. The specific cellular 
actions of LPA are determined by its multifaceted molecular structures, the 
expression of multiple G-protein coupled LPA receptors at the cell surface and their 
diverse coupling to intracellular signalling pathways. Numerous studies have now 
shown that LPA has thrombogenic and atherogenic actions (Schober & Siess, 2012). 
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Aim of the study 
 
The principal aim of this study was to reproducibly isolate and thoroughly 
characterize human arterial SMC subpopulations in order to evaluate their role in 
atheroma formation and their phenotypic changes associated to the atherosclerotic 
process. Additional aim of this study was to analyze the expression profiles of human 
arterial SMC subpopulations, in particular to validate signals stemming from a 
previous microarray study. In addition investigations of these signals both at RNA 
and protein level, on cultured SMCs cells and on carotid tissues directly, was 
addressed. 
The feasibility of this study has been largely supported by  well-established 
collaborations between our laboratory and i) the Unit of Vascular and Endovascular 
Surgery of Sant’Anna University Hospital, of Ferrara, leader Francesco Mascoli, who 
provided us with  samples of atherosclerotic and non-atherosclerotic human carotid 
artery from patients undergone to carotid endarterectomy and ii) the group of Marie 
Luce Bochaton Piallat of the Department of Pathology and Immunology (CMU) at 
the University of Geneva, for its expertise on SMC characterization by istological, 
immunoistochemical and immunofluorescence analysis. 
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Materials and Methods 
 
Tissue explantation 
 
Carotid endo-arterectomy (CEA) specimens were obtained at surgery from thirty 
patients who underwent conventional CEA for extracranial high-grade internal 
carotid artery stenosis (>70% luminal narrowing for symptomatic patients according 
to NASCET criteria for carotid stenosis11). Arteriotomy was performed on the 
common carotid artery and extended to the internal carotid artery. The specimen was 
removed intact as a single piece and was further cut into two portions: non-diseased 
portion (NP) and diseased portion (DP), characterized by diffuse atherosclerotic 
lesions. Representative tissue blocks were obtained from each segment and processed 
for immunohistochemistry or immunofluorescence. 
For cell culture specimens retrieved at surgery were conserved in cold sterile Roswell 
Park Memorial Institute (RPMI) supplemented with 2% HEPES, 100 U/ml penicillin, 
100 μg/ml streptomycin and 2 mM L-glutamine (Gibco-Invitrogen, Carlsbad, CA). 
Specimens were carried to the laboratory with in 1 hour from surgical intervention. 
Specimens were washed several times with warm (37°C) phosphate buffered saline 
(PBS) to remove blood in excess. 
The abluminal surface of tissue were gently scraped to remove any connettive tissue, 
whereas the luminal surface underwent the same treatment to remove endothelial 
cells. For tissue explantation, (CEA) specimens were cut into 3x3x3-mm pieces. The 
abluminal side of the explants was carefully placed in contact with the culture dish 
(5-10 tissue pieces for the nondiseased portion NP and 15- 20 tissue pieces for the 
diseased portion DP per 60-mm dish). After 20 minutes, during which specimens 
dried, RPMI (10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 400mM l-
glutamine) was added to petri dish.  
 
Cell Culture 
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Once outgrowth from explanted tissue rinse confluences, cells were passed by a 1:2 
spit ratio and cultured in RPMI plus 10% FBS, containing 100 U/ml of penicillin and 
100 μg/ml of streptomycin and 400mM l-glutamine (All reagent from Gibco, 
Invitrogen).Cells were maintained at 37 °C in a humidified atmosphere of 95% air 
and 5% of CO2. Cells were usually used at third and four
th
 passage. The mean 
proportion of explants yielding SMC outgrowth was higher for the NP media than for 
the DP media. Although large SMCs started to grow from the explants more rapidly 
than did small SMCs (at 5-7 and 6-10 days, respectively), small SMCs reached 
confluence after 10-14 days from the appearance of the first cells whereas large 
SMCs only formed subconfluent monolayers at 14-21 days. Explanted tissue pieces 
were removed 7 to 10 days after the first SMCs appeared. Both phenotypes remained 
stable after several passages. 
 
Co-culture experiments 
 
Co-culture of plaque and macrophages with large cells was performed by using the 
Transwell system (24-mm diameter Transwell clear polyester membrane, 0.4-μm 
pore size, Costar). Plaque-derived conditioned medium (CM) was collected from 
cultures of DP plaque pieces 72 hours after plating. CM was diluted 1:1 (v/v) with 
fresh medium supplemented with 10% FBS and added to passaged SMCs for 72 
hours. Large cells were plated into the lower compartment in RPMI plus 10% FBS, 
plaque and macrophages were plated in the upper compartment. CaM inhibition was 
accomplished with N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide (W-7; 
Fluka/Sigma-Aldrich). To evaluate the effect of W-7 on phenotypic transition, large 
SMCs were plated in RPMI supplemented with 10% FBS at a density of 80 
cells/mm2 with or without plaque-derived conditioned medium (CM) in combination 
or not with W-7 (10 µM) for 3 (immunofluorescence staining) or 7 (cell proliferation) 
days.  
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RNA extraction  
 
RNA was extracted both from cells and tissue specimens. Cells were directly lysed in 
a culture dish by adding 1 ml of Trireagent® solution (SIGMA) to a 3.5 cm diameter 
dish. A more complex process was used for the lysis of the sample tissues. In fact, NP 
and DP specimens were collected immediately in liquid nitrogen after surgical 
operation. They were conserved at -80°C until further processing. Specimens were 
cutted into slides of 10 µm with cryostat and 1 mL of was added for 50-100 ng of 
tissue. 
The mixture was drawn up and down with a small bead inside a 2 ml heppendorf 
through tissue lyser to help break up. The heppendorf was perturbed for 2 minute at 
20 Hz. After it was chilled in ice and again was perturbed for 2 minute at 20 Hz. 
To remove insoluble material from the homogenate a centrifugation at 12,000 g for 
10 minutes at 4°C was performed. The resulting pellet contains extracellular 
membranes, and high molecular weight DNA, while the supernatant contains RNA. 
In samples with fatty acids as DP portions, an excess of fat collects as a top layer 
were removed. In each case, the cleared homogenate solution was transferred to a 
fresh tube. From this step the procedure is the same for cells and tissues. 
200 μL of chloroform was added and the mixture was shaken vigorously by hand for 
15 s. The mixture was incubated for 3 min at room temperature and then centrifuged 
at 12,000 g for 15 minutes at 4°C to separate the 3 layers. The upper, aqueous, phase 
contains mostly RNA, and the interphase contains mostly DNA. 
A 500 μL aliquot of the aqueous phase was collected in a fresh tube and an equal 
volume of cold isopropanol was added. The mixture was chilled on ice for 10 min 
and then centrifuged at 12,000 g for 10 min at 4°C to yield an RNA precipitate. 
The pellet was identified and the supernatant discarded. The pellet was washed with 
1ml of 70%  cold ethanol at 4°C and then dried at room temperature to ensure that no 
contaminating ethanol remained. 
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Ribonuclease-free water (treated with diethylpyrocarbonate) was added (20-40 μL, 
depending on the size of the RNA pellet) and the RNA concentration was determined 
by spectrophotometry. The quality of the RNA was valued with 1% of agarose gel. 
 
Reverse transcription and Real-Time Quantitative PCR 
 
The RNA quality and quantity were determined by Experion RNA StdSens Analysis 
Kit (BioRad, Hercules, CA) or checking on 1% agarose gel. For each sample 1μg of 
total RNA was reverse transcribed using SuperScript VILO cDNA Synthesis Kit 
(Gibco-Invitrogen) according to the manufacturer’s recommendations in the 
following thermal conditions: 10 minutes at 25°C, then 60 minutes at 42°C, followed 
by 5 minutes at 85°C. Specific primers for human NOV, CCN2, ENPP2, B2M, 
ACTB and 18S mRNA were designed as follows: 5’- 
TGAGATGCTGAAACAGACTCGGCT-3’ (forward) and 5’- 
TTGAGTGACTTCTTGGTGCGGAGA -3’ (reverse) covering a fragments of 111bp  
of NOV, 5’- CTTGCGAAGCTGACCTGGAA -3’ (forward) and 5’- 
AAAGCTCAAACTTGATAGGCTTGGA -3’ (reverse) covering a fragments of  
90bp   of CCN2, 5’- TATCCTGCTTTCAAACGGGTCTGG -3’ (forward) and 5’- 
GTTGGAACAGGAATGGAACTGCCT -3’ (reverse) covering a fragments of  182 
bp of ENPP2, 5’- TTTCATCCATCCGACATTGA -3’ (forward) and 5’- 
CCTCCATGATGCTGCTTACA -3’ (reverse) covering a fragments of  228bp   of 
B2M, 5’- CATCGAGCACGGCATCGTCA -3’ (forward) and 5’- 
TAGCACAGCCTGGATAGCAAC -3’ (reverse) covering a fragments of  211bp   of 
ACTB and 5’-GTAACCCGTTGAACCCCATT-3’ (forward) and 5’-
CCATCCAATCGGTAGTAGCG-3’ (reverse) covering a fragments of  153bp of 
18S. Specific primers for human CALM1, CALM2, CALM3 were designed as 
follows: 5’-TGACTTCCCCGAATTTTTTGAC-3’ (forward) and 5’-
TGTCCGTCTCCATCAATATCT-3’ (reverse) covering nucleotides 394 to 609 of 
CALM1, 5’-AAGTTGATGAAATGATCAGGGAAG-3’ (forward) and 5’-
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TGAAGTCCTAATTACTATACATGCATA-3’ (reverse) covering nucleotides 520 
to 739 of CALM2, 5’-ATGATGACTGCAAAGTGAAGGCCC-3’ (forward) and 5’-
GAGCAATCATGCAGCTTGGGACAA-3’ (reverse) covering nucleotides 613 to 
797 of CALM3. Real time SsoFast EvaGreen Supermix PCR (BioRad) was 
performed in a Chromo4 Real-Time PCR Detection System (BioRad). Denaturation 
was performed at 95°C for 30 seconds, then DNA was amplified for 40 cycles of 5 
seconds at 95°C, and 10 seconds at 60°C. Each reaction was performed in triplicate. 
The relative levels of each RNA were calculated by the comparative CT method. 
Results were normalized to amplified 18S, or/and B2M and ACTB transcripts in the 
same samples and were expressed as fold change in small compared to large SMCs 
and plaque-derived CM treated large SMCs to untreated large SMCs. Each real-time 
PCR experiment was repeated at least twice. 
 
Antibodies 
 
The following primary mouse monoclonal antibodies were used: IgG2a recognizing 
α-smooth muscle actin (α-SMA) clone 1A412; IgM recognizing S100A4 (clone 
4B4); IgG1 recognizing calmodulin (CaM, clone CaM85, Zymed-Invitrogen, 
Carlsbad, CA); IgG1 recognizing smoothelin A and B (clone R4A); IgG1 recognizing 
CD68, marker of macrophages (clone KP1, Dako); Rabbit polyclonal IgGs 
recognizing NOV (clone GTX103377, Gene Tex) was also used. 
 
Immunofluorescence cell staining 
 
Cells from 3rd to 6th passage were growth on glass cover slips. SMCs were fixed for 
20 minutes using 1% paraformaldehyde (PFA) (Sigma Aldrich) in RPMI with 2% 
HEPES (Gibco, Invitrogen Corporation) then rinsed in Phosphate Buffered Saline 
(PBS). They were further incubated for 7 minutes in methanol at -20°C and double 
stained with anti-α-SMA and either anti-NOV or anti-CaM; Rhodamine-conjugated 
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goat anti-mouse IgG1, fluorescein-conjugated goat anti-mouse IgG2a and rhodamine-
conjugated goat-anti-rabbit IgG were used as secondary antibodies (Southern Lab, 
Birmingham, AL). 
Nuclei were stained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, 
Fluka/Sigma-Aldrich). Slides were mounted in buffered polyvinyl alcohol (PVA) 
(Fluka/Sigma-Aldrich). SMC images were taken by means of an Axioskop 2 
microscope (Carl Zeiss, Jena, Germany) equipped with oil immersion Plan-Neofluar 
×40/1.4 and ×63/1.25 objectives and a high sensitivity, high-resolution digital color 
camera (Axiocam, Carl Zeiss). The number of αSMA, NOV and CAM-positive cells 
was counted by using an Eclipse 50i microsope (Nikon) at x40 magnification in 10 
different fields for each sample. Images of immunofluorescence staining were 
acquired and overlaid by using Adobe Photoshop. 
 
Immunofluorescence tissue staining 
 
Three μm thick sections from formalin-fixed paraffin-embedded specimens were 
incubated in tris/EDTA pH 9.1 for 20 minutes in microwave at 250W. Double 
immunofluorescence staining was performed with anti-α-SMA (1:50) and anti-Nov 
(1:400). Rhodamine-conjugated goat anti-rabbit IgG and fluorescein-conjugated goat 
anti-mouse IgG2a were used as secondary antibodies (Southern Lab, Birmingham, 
AL). Nuclei were stained with DAPI. Slides were mounted in buffered polyvinyl 
alcohol. Images were taken as described above. 
 
Immunohistochemistry 
 
Representative specimens of the NP (n=3) and DP (n=3) from the same patient and 4 
additional DP specimens were fixed with 4% buffered formalin and embedded in 
paraffin. Three μm thick sections were stained with standard histological techniques: 
hematoxylin and eosin (HE), Masson trichrome and Miller. Immunostaining for α-
33 
 
SMA (1:200), NOV (1:500), CD68 (1:200) was performed on adjacent sections. 
Before using the first antibody, immunoreactivity was intensified by microwave 
treatment (750W, 5 minutes) in citrate buffer (10 mM, pH 6.0) for α-SMA, by 
pressure cooker treatment in citrate buffer 3 minutes for NOV. Goat anti-mouse or 
anti-rabbit biotinylated antibodies (Dako, Glostrup, Denmark) were used as 
secondary antibodies. The presence of the specific proteins was revealed by means of 
the streptavidin-biotin peroxidase complex and staining was visualized with the 3,3'-
diamino-benzidine (Dako). Hemalun was used as counterstaining. Images were taken 
by means of an Axioskop 2 microscope (Carl Zeiss, Jena, Germany) equipped with 
Plan-neofluar ×10/0.3 and oil immersion Plan-Neofluar ×40/1.4 objectives and a high 
sensitivity, high-resolution digital color camera (Axiocam, Carl Zeiss). 
 
Statistical Analysis 
Comparisons between treated and control groups were analyzed by Student t test. 
Multiple comparisons were performed by ANOVA. Differences were considered 
statistically significant at values of P<0.05. 
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Results 
 
Isolation of SMCs by tissue explantation 
 
In order to obtain primary culture of SMCs from CEA specimens, from both diseased 
portion (DP) and grossly normal portion (NP) tissue explantation technique was used. 
After four days, from tissue explantation, wells containing specimens were observed 
daily with phase-contrast microscopy, to record cellular outgrowth. 
Cells outgrew from fifth to tenth day after tissue explantation but time for outgrowth 
was different, in fact cells from NP came out before cells from DP. After two weeks 
specimens were removed from well. 
Confluence was rise at different days, in fact while NP cells raised the confluence 
nine days after cellular outgrowth, DP cells took about seven day to raise confluence. 
 
Distinct SMC phenotypes 
 
Observation of cells by phase-contrast microscopy clearly showed morphological 
differences between NP- and DP-derived cells (figure 9) 
 
  
 
 
 
 
 
Figure (9). Phase-contrast micrographs showing large SMCs isolated from the media of the 
proximal (“normal” portion NP) portion (a), and small SMCs isolated from the media of the distal 
diseased portion (DP) (b).  
 
a b 
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Cells from NP are “large”, grow as a monolayer and exhibit flat morphology at 
confluence, while DP cells are “small” and grow multilayer with the classic "hill-and-
valley" growth pattern. 
 
Distinctive features of SMC 
Differences between the two cell populations were further analyzed by investigating 
the expression of a characteristic molecular marker of the SMC lineage. For this 
purpose immunofluorescences staining was used. Since mature SMCs express alpha 
smooth muscle actin (α-SMA) identification of this marker in these cells is necessary 
to define them as smooth muscle cells. In parallel, the expression of S100A4, a small 
calcium-binding protein marker of atheroma-prone SMCs in pig (Brisset et al, 2007), 
was analyzed at the Department of Immunology and Pathology in Geneva, in the 
same cell populations cultured at the lab in Ferrara. 
 
 
 
 
 
 
 
 
 
Figure (10). Immunofluorescence staining of large (a, c) and small (b, d,) SMCs for α-SMA (a, b) 
and S100A4 (c,d). Nuclei are stained in blue by DAPI. Note that α-SMA is located in stress fibers 
in large SMCs (a) whereas it shows a more diffuse pattern in small SMCs. S100A4 is diffusely 
expressed in small SMCs (d). Bar= 20 µm. 
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The majority of large SMCs (82.9±8.8%) displayed a typical α-SMA staining pattern 
with strongly positive stress fibers (Figure 10, a); both the number of α-SMA positive 
cells (68.8±12.1%) and the intensity of the staining was lower in small SMCs (Figure 
10, b) compared to large SMCS. Large SMCs stained negative for S100A4 (Figure 
10, c) whereas small SMCs expressed S100A4 (42.0±6.6%) with a diffuse staining 
pattern (Figure 10, d). 
 
Isolation and Characterization of Plaque-Derived Macrophages 
 
Many round cells (50-100 for each explant) emerged from the DP plaque explants 24- 
48 hours after plating (n=3). They displayed a flattened appearance (figure 11, a) and 
a foamy cytoplasm. Positive staining for CD68 (figure 11, b) identified them as 
macrophage-derived foam cells. 
Macrophages remained viable in culture for a period of 3 to 4 weeks, then they 
started detaching. 
 
 
 
 
 
Figure (11).Characterization of macrophage-derived foam cells. Phase-contrast image (a) and CD68 
(b) staining. These cells are positive for CD68, marker of the macrophage lineage. Bar= 50 μm. 
 
Plaque, Plaque-Derived Macrophages and Plaque-Derived CM Induce SMC 
Phenotypic Transition 
 
Large cells and plaque or macrophages were placed in two different compartments. 
Transwell membranes (Corning Corporation) were used, a system suitable for 
coculture experiments. This polyester membrane is supported on a plastic small 
 b 
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basket, inserted in wells (made of polystyrene). The membrane has holes of 0,4μ that 
does not allow the cells to cross it, but permit medium to diffuse from a compartment 
to other. The transwell system could permit to grossly mimic the structure of the 
vessel wall, in which cells of media and plaque are separate by elastic lamina, but 
they can communicate and influence each other by secreting biological molecules, 
able to diffuse from a compartment to another. The cells were located in the bottom 
and were cultured in three different conditions, in the presence of: macrophages or 
plaque located in the upper compartment (fig 12, a; c) and conditioned medium added 
directly to the cells (fig 12, b).  Conditioned medium was collected from cultures of 
DP plaque pieces 72 hours after plating. CM was diluted 1:1 (v/v) with fresh medium 
supplemented with 10% FBS and added to passaged SMCs for 72 hours. 
 
 
                                              
 
 
 
Figure (12).Schematic representation of cell growth system. 
 
 
After coculture with plaque pieces from the DP, plaque-derived macrophages, or 
culture with plaque-derived CM, large SMCs underwent a transition from the flat, 
polygonal morphology to the small, elongated appearance typical of small SMCs. 
(Fig 13 A). 
 b  c 
Large cells Large cells Large cells 
Plaque CM Macrophages 
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By immunofluorescence we observed that the transition from large to small 
phenotype was associated with a diffuse α-SMA staining and a reduced α- SMA 
content. This transition occurred in the majority of large cells (Fig 13 B). 
 
 
Figure (13). SMC phenotypic transition. A. Phase-contrast images of large SMCs in control  
condition (a) and after culture with plaque derived CM (b). B. Immunofluorescence staining of 
large SMCs in control conditions (a, c, e) and after culture with plaque derived CM (b, d, f) for α-
SMA (a, b), and CaM (c, d). Double-labeled structures appear in yellow on merged pictures (e, f). 
Nuclei are stained in blue with DAPI.  
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While we were studying the changes in the phenotype and proliferation promoted by 
the treatment with plaque, plaque-derived CM, and plaque-derived macrophages, the 
group of Marie-Luce Bochaton Piallat in Geneva performed proteomic analysis on 
large and small populations, which have been cultured in our laboratory in Ferrara. 
From the analysis of 2D-PAGE spots calmodulin (CaM) emerged as differentially 
expressed between cell populations, particularly it was predominantly expressed in 
small cells. 
By immunofluorescence analysis we observed that large to small phenotypic 
transition, induced by the different treatments (see above), was associated with a 
significant increase in the proportion of CaM-positive cells (fig 13, c; d).  
When large SMCs were cocultured with plaque pieces from the DP (n=3) or plaque-
derived macrophages (n=2) they grew more rapidly compared with control condition 
(large alone, percent growth rate at 7 days 193.226.9%, P<0.001, and 177.361.4%, 
P<0.01, respectively; figure 13, a). Similar results were obtained when large SMCs 
were cultured with plaque-derived CM (n=3; percent growth rate at 7 days 
234.364.4%, P<0.01; figure 13, a). 
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Figure (14). SMC phenotypic transition. Proliferative activity (a) and quantification of typical -
SMA (b) and CaM (c) positive SMCs in control conditions, after coculture with plaque pieces from 
the DP and plaque-derived macrophages, after culture with plaque-derived CM and after co-
treatment with W-7. **, P<0.01 and ***, P<0.001 compared with control; #, P<0.05 compared with 
culture with plaque-derived CM. 
 
CaM inhibition with W-7 
 
W-7 was chosen as a CaM inhibitory compound to investigate if inhibition of CaM 
could prevent the phenotypic changes, observed after treatment with macrophage-
derived foam cells or atherosclerotic plaque conditioned media.  
Large SMCs populations were plated in RPMI medium with or without plaque 
derived CM in combination or not with W7. We found that the proliferative effect of 
plaque-derived CM (Figure 14, a; percent growth rate at 7 days 67.7±32.77%) on 
large SMCs was prevented by co-treatment with W-7 (percent growth rate at 7 days 
29.76±21.16%).  
Immunofluorescence staining (Figure 15 and 14, b;c) showed a significant increase in 
the number of typical α-SMA-positive SMCs (n=2; 37.2±7.2%) accompanied by a 
reduction in the percentage of SMCs displaying a diffuse and/or practically negative 
α-SMA staining (62.8±7.2%) compared with SMCs treated with plaque-derived CM 
(15.9±4.7% and 84.1±4.0%, respectively, P<0.05 for both).  
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Figure (15). SMC. Immunofluorescence staining of large SMCs in control conditions (a, c, e) and 
after culture with plaque derived CM + W7 (b, d, f) for α-SMA (a, d), and CaM (b, e). Double-
labeled structures appear in yellow on merged pictures (c, f). Nuclei are stained in blue with DAPI.  
 
CALM mRNA Expression  
 
We investigated the RNA expression levels of the three genes for CALM on cultured 
SMCs by QPCR. Level of CALM1, CALM2 and CALM3 were found similar in 
small (n=3) and large (n=3) SMC populations (fold change 1.63±0.87, 1.93 ±0.27, 
and 1.66±0.29, respectively). The large to small phenotypic transition was not 
associated with significant differences in the fold change of CALM1, CALM2 and 
CALM3 mRNA expression after coculture with plaque pieces from the DP (n=2; 
0.87±0.15, 1.29±0.33, and 1.01±0.14, respectively) or plaque-derived macrophages 
(n=2; 0.61±0.23, 1.10 ±0.79, and 1.25±0.25, respectively), and after culture with 
plaque-derived CM (n=1; 1.43, 1.24, and 1.49, respectively) compared with untreated 
large SMCs (n=3). 
 
RNA studies in Cultured SMCs and in tissue specimens 
 
a b c 
d e f 
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An additional aim of this study was to analyze the expression profiles of human 
arterial SMC subpopulations, in particular to validate signals stemming from a 
previously conducted RNA microarray study in our laboratory.  
The analysis was also extended to carotid tissues directly both at RNA and protein 
level. 
The RNA profiling microarray study, which was conducted on a small number of 
RNA samples, from three couples of small and large populations, showed 255 genes 
differentially expressed (fold change >2; P<0.05).  
To validate by qPCR signals from RNA profiling, for each gene  we designed one of 
the two primers in the same exon recognized by the probe used in the microarray, in 
order  to analyze approximately the same region tested by the microarray approach.  
We decided to investigate NOV because it was one of the genes found more 
expressed in small than in large cell populations in the RNA profiling (by using  two 
different probes, fold change small/large populations = 4.54 and 4.77 respectively, 
P<0.05).  
NOV mRNA level evaluation by qPCR was conducted in cell populations (n=8) 
cultured from couples (n=4) of NP and DP carotid portions. NOV mRNA was found 
more expressed in cells (small) obtained from the DP than in those (large) from the 
respective NP  (fold change D/N=2.19±0.51 and 2.62±0.8 using 18s and B2M as 
control genes respectively). 
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Figure (16). QPCR of NOV in large and small populations, 18S and B2M are used as control 
genes. . Large cells are set to one as control. Data are reported as mean±SEM. P=ns 
 
The study of NOV mRNA expression levels was further extended to 5 populations of 
large and 5 populations of small cells from different CEA specimens. Significant 
differences were observed in expression levels (fold change small/large populations= 
2.10±0.63, P<0.05 by unpaired t-test).  
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Figure (17). QPCR of NOV in large and small populations, B2M is used as control gene. Data are 
reported as mean±SEM. *=P<0.05 
 
As these results were obtained in culture of SMCs, a model that does not reproduce 
the in vivo condition, and can cause a shift in the transcriptome (Bijnens et al, 2005), 
we decided to “go back” to the tissue removed by carotid endarterectomy.  
 Thus, to investigate RNA expression level directly in the tissue from which SMC 
primary cultures were obtained by tissue explantation, we analyzed the RNA 
extracted from 4 couples of diseased and normal portions of carotid artery. A higher 
expression of NOV in DP than in NP was detected (fold change DP/NP= 2.24±1.10 
and 2.27±1.45 using as refer genes ACTB and 18s respectively, P=ns).  
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Figure (18). QPCR of NOV in NP and DP populations, 18S and B2M are used as controls. mRNA 
levels of the NP portions are set to one as control. Data are reported as mean±SEM. 
 
Taken together, results from qPCR for NOV mRNA indicated that the fold change in 
expression levels between cultured small and large cell populations was similar to 
that between DP and NP tissue specimens.  
Successively we wondered if genes, coding for proteins interacting with NOV could 
be differentially expressed in the SMC subpopulations. From the literature NOV is 
involved in many pathways and the inspection of STRING database revealed that 
NOV interacts with many other proteins (fig. 19) and among these, CCN2 (CTGF) 
which belongs to the same family of NOV. 
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Figure (19). Interactions of NOV with other genes/proteins. This image is taken from the following 
web site: http://string-db.org/ . 
 
Interestingly previous studies have reported CCN2 expression levels much more 
higher in smooth muscle than other tissue (Fig. 20). 
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Figure (20). CCN2 levels by microarray analysis in different human tissues. The figure is taken 
from the following link and shows a study of microarray conducted in human tissues. The bars are 
representative of quantity of CCN2 in the different districts. The highest expression here 
represented as out of scale is in the smooth muscle tissue.  
 
By qPCR we analyzed CCN2 mRNA levels in 4 couples of small and large cell 
populations. CCN2 mRNA levels were found slightly higher in cells cultured from 
the DP (small cells) than in cells from the NP (large cells) (fold change small/large 
populations=1.36±0.40 and 1.81±0.67 using ACTB and 18S as control genes 
respectively, P=ns).  
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Figure (21). QPCR of CCN2 in large and small populations, ACTB and 18s are used as control 
genes. Data are reported as mean±SEM.  
 
As for NOV, we investigated the RNA levels for CCN2 also at tissue level, NP and 
DP specimens. CCN2 mRNA was found more expressed in NP than in DP (fold 
change DP/NP=0.69±0.12 and 0.39±0.09 using ACTB and 18s as control genes 
respectively, P=ns).  
 
 
 
 
 
 
 
 
Figure (22). QPCR of CCN2 in NP and DP, ACTB and 18s are used as housekeeping genes. Data 
are reported as mean±SEM. 
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The analysis of the chromosome 8 region (8q24) encompassing the NOV gene 
showed that downstream to NOV is located the ENNP2 gene that codes for autotaxin 
the enzyme that generates LPA (see introduction). Thus ENPP2 gene was selected for 
further analysis at RNA levels both in cultured SMC populations and in carotid 
tissues. 
From the literature, the ENPP2 mRNA levels in smooth muscle evaluated by 
microarray (fig. 23) were comparable to those of NOV mRNA (fig 7 introduction). 
 
Figure (23). ENPP2 levels by microarray analysis in different human tissues. The figure is taken 
from the following link http://www.genecards.org/ and as below, shows a study of microarray 
conducted in human tissues. The bars are representative of quantity of ENPP2 in the different 
tissues.  
 
QPCR for ENPP2 was conducted in 3 large and in 3 small cell populations. Although 
significant differences were not observed, a trend for a higher expression of ENNP2 
mRNA in small than in large was detected (fold change small/large 
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populations=5.67±2.36 and 4.02±1.69 using ACTB and 18S as control genes 
respectively).  
In the previously performed RNA microarray in SMC subpopulations, a higher fold 
change for ENPP2 was found between small and large cell populations (P value < 
0.05).  
 
 
 
 
 
 
 
 
 
Figure (24). QPCR of ENPP2 in large and small populations, ACTB and 18s are used as 
housekeeping genes. Data are reported as mean±SEM. P=ns 
 
Also analysis of  mRNA levels in tissues showed that  ENPP2 mRNA levels were 
higher in DP( n=4) than in NP ( n=4) specimens (fold change DP/NP=1.99±0.64 and 
1.72±0.56 using 18S and ACTB as control genes respectively, P=ns). 
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Figure (25). QPCR of ENPP2 mRNA  in NP and DP, ACTB and 18s are used as housekeeping 
genes. Data are reported as mean±SEM. 
 
Immunofluorescence of NOV in large and small SMCs  
 
We investigated the expression of NOV protein in cultured SMC populations by 
immunofluorescence. We analyzed 5 large and 4 small populations of SMCs. For 
each population, cells were seeded at the density of 50000 for each well (six-well 
plate). Positive cells for the marker of differentiation, α-SMA, and the NOV protein 
were counted in 10 different fields for each sample. 
The large SMCs displayed a typical α-SMA pattern (stress fibers) and the 49.8 ± 
7.27% of cells was strongly positive. Among the small cells, the 31.7 ± 12.76% was 
positive for α-SMA with a diffuse staining. While 23.01 ± 3.38% of small SMCs was 
positive for NOV, only 4.72 ± 1.95% of large cells was positive. Thus a 4.87 fold 
change in immunofluorescence signal for NOV between small and large populations 
was observed.  
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Figure (26). Immunofluorescence staining of large (a, b, c) and small (d, e, f) SMCs for α-SMA (a, 
d), NOV (b, e) and merge (c, f). Nuclei are stained in blue by DAPI.  
 
Histological characterization of arterial tissues 
 
This part of the research was conducted during my five month stage at the laboratory 
of Marie-Luce Bochaton Piallat in Geneva.   
Representative tissue blocks obtained from  NP (n=3) and DP (n=10) specimens were 
processed for histology characterization. All CEA specimens included the entire 
intima and the media comprising the layers up to the external elastic lamina. NP 
specimens exhibited a media and a thin thickened intima, consistent with American 
Heart Association (AHA) type III intermediate lesion (Figure 26, a, c and e). DP 
specimens exhibited a media underlying an atheromatous plaque corresponding to 
AHA type IV-V atheroma-fibroatheroma (Figure 26, b, d and f). Miller and Masson’s 
trichrome staining showed the typical structure of a muscular artery with abundant 
elastic fibers in the media (Figure 26, c, d, e and f). The atherosclerotic plaques of the 
carotid artery showed in all the samples a substantial fibrous cap overlying the 
necrotic core containing extracellular lipids in which cells were totally absent. The 
atherosclerotic lesions were composed of a large number of SMCs cells.  
Calcifications were present near cholesterol clefts in one of the samples.  
 
 
 
 
 
 
 
 
 
 
53 
 
 
Figure (27). Histological and immunohistochemical features of the NP (a, c, e, g, i, o,) and DP (b, d, 
f, h, j, p) from human CEA specimens. HE (a, b), Masson tricrome (c, d) and Miller(e, f) staining 
show that the NP (a, c, e) and DP (b, d, f) correspond to type III and IV-V lesions (AHA 
classification) respectively. Bar= 200 μm.  
 
NOV expression in human atherosclerotic lesions 
 
By immunohistochemistry NOV was found more strongly expressed in plaque than in 
the underlying media, whereas a large number of cells were faintly stained in the NP 
media (Figure 28; e, f). 
As expected all SMCs of media from the NP and DP and intimal thickening of the 
NP and plaque from the DP were positive for α-SMA, a well-accepted differential 
marker of SMCs (figure 28; a, b). Numerous CD-68 positive macrophages (Figure 
28; c, d), were present in the plaque of the DP, but few cells were detected in the 
intimal thickening in 2 of the 3 NP specimens.  
 
 
 
 
 
 
 
 
 
 
 
Figure (28). Immunostaining for α-SMA (a, b), shows that all SMCs in the media of the NP and DP 
express SMC differentiation markers. CD68-positive macrophages (c, d) are present in the lesion of 
a b 
c d 
e f 
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the DP. NOV (e, f) is strongly positive in the plaque of DP portion, but faint staining is present in 
the NP specimens. Inset magnification is x4. The lumen is located on the left side of the pictures.  
 
The analysis of NOV protein expression at tissue level was also conducted by 
immunofluorescence. Double immunofluorescence staining (Figure 29) performed 
with anti NOV and anti α-SMA on DP specimens showed that NOV was expressed in 
a fraction of SMCs located near the lumen (Figure 29, b).The signal of NOV is 
probably given not only by SMCs but also by macrophages that express this protein. 
Staining for α-SMA (Figure 29, a) showed that SMCs were positive for NOV (Figure 
29, c). The auto-fluorescence of the elastic fibers hampered the detection of NOV 
positive cells in the media.  
All together data obtained on tissue blocks by immunohistochemistry (NP and DP 
portions) and immunofluorescence (DP portions) indicated the presence of a strong 
positive signal for NOV in the plaque given in part by SMCs. 
 
 
 
 
 
 
 
Figure (29). Double immunofluorescence staining showing the expression of α- SMA (green; a)  
and NOV (red; b) in the atherosclerotic plaque of DP from human CEA specimen. Double-labeled 
structures appear in yellow on merged pictures and arrowheads highlight double-labeled cells (c). 
NOV is expressed by α-SMA-positive intimal SMCs (c). The vessel lumen is located on the left 
side of the pictures.  
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Discussion 
 
The principal aim of this thesis work was to reproducibly isolate and 
thoroughly characterize human arterial SMC subpopulations in order to investigate 
their role in atheroma formation. Atherosclerotic and grossly non atherosclerotic 
portions of carotid artery represent an appropriate source of SMCs, and an ideal 
model to detect changes in SMCs phenotype and in gene expression potentially 
associated to the atherosclerotic process. Moreover the human origin of the 
“material” studied gives strength to this experimental approach.  
The present study shows the conditions to reproducibly isolate two distinct 
SMC populations, small and large, from human CEA samples. Large SMCs exhibit 
many biological features similar to those described for rat aorta (Bochaton-Piallat et 
al, 1996) and porcine coronary artery (Hao et al, 2002) SMCs referred to as spindle- 
shaped SMCs whereas small SMCs resemble rat epithelioid (Hao et al, 2002) and 
porcine (Faxon et al,  2004) rhomboid (Hao et al, 2002) SMCs. Some differences 
however exist between small SMCs and the atheroma-prone SMC subpopulations 
described in other species such as rat, pig and cow: rat epithelioid, porcine rhomboid 
and cow epithelioid/rhomboid SMCs are cobblestone and grow as a monolayer at 
confluence, whereas human small SMCs are fusiform with a hill-and-valley growth 
pattern. Interestingly, a similar phenotype was described in human SMC populations 
isolated from the media of aorta and renal artery by Björkerud (Björkerud, 2005). 
Despite progress in understanding arterial SMC biology, several questions 
remain open such as the relative contribution of a distinct SMC subpopulation to 
atheroma or restenosis formation. The concept that SMCs within the media are  
heterogeneous and that a predisposed SMC subpopulation is prone to accumulate into 
the intima is based on the observations by Benditt and Benditt in 1973, further 
confirmed by other authors (Murry et al, 1997; Van der Loop et al, 1996). SMC 
heterogeneity has been studied in many experimental models (Walker et al, 1986; 
Hao et al, 2002) and suggested in humans in several situations (Horekhovet al, 1986; 
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Babaev et al, 1992). Moreover, a clonal SMC subpopulation exhibiting features 
compatible with the atheroma-prone phenotype has been isolated from the undiseased 
mammary artery (Li et al, 2001). 
In my thesis we showed that different culture conditions, as plaque-derived 
macrophages or atherosclerotic plaque conditioned medium (CM), promote the 
transition of large to "small SMCs". This would not imply clonally or otherwise 
distinct subsets of SMC subpopulations. Thus a single clear paradigm concerning the 
contribution of a distinct SMC subpopulation to atheroma or restenosis cannot be 
formulated. 
The different treatment conditions used for large SMC cultures, with plaque-
derived macrophages or atherosclerotic plaque CM or plaque, were also aimed to 
investigate the origin of the stimuli involved in SMC migration from the media to the 
intima and the parallel phenotypic transition. 
Our experimental setting suggest that factor(s) released by plaque and/or plaque-
derived macrophages could be necessary for the transition from large to small 
phenotype, further indicating a complex interaction between the two cell types. This 
factors, such as cytokines (Ross, 1999) and oxidized LDLs (Mertens et al, 2001) 
released by macrophages and/or foam cells, could promote the selective recruitment 
of SMCs from the media during the in vivo process.  
The characterization and comparison of the two subpopulations, isolated from 
diseased and grossly normal portions of carotid artery, showed that CaM is 
overexpressed by small SMCs in vitro. 
Mammal CaM is encoded by 3 genes (CALM1, CALM2, and CALM3) at different 
chromosomal locations. CaM is a small acidic 4 EF-hand calcium binding protein 
ubiquitous in eukaryotes where it represents the main calcium sensor (Chin et al, 
2000).  Increased intracellular calcium activates CaM which in turn regulates 
different protein targets (CaM-binding proteins) finally affecting many cellular events 
(e.g. cytoskeletal organization, muscle contraction, gene regulation and cell growth) 
(O’Day, 2003). The selective activation of CaM binding proteins rely on CaM 
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concentration and the number of bound calcium ions (Chin et al, 2000; O’Day, 
2003 ).The crucial role of calcium/CaM signaling in cell cycle regulation is well 
established (Reddy et al, 1992). Recently, it has been demonstrated that G1/S 
transition is at least partly mediated by calcium/CaM-dependent cyclin E/CDK2 
activity (Choi et al, 2006). Moreover a synthetic peptide blocking CaM–cyclin E 
interaction arrests S-phase entry and results in decreased proliferation of human and 
mouse SMCs (Hui et al, 2011). In the present study we show that small SMCs, 
overexpressing CaM, proliferate more actively than large SMCs and that large to 
small phenotypic transition is accompanied by a strong increase in CaM expression. 
However protein levels were not paralleled by significant variations in CALM1, 
CALM2, and CALM3 mRNA, suggesting that the different levels of CaM are the 
result of post-transcriptional mechanisms (Toutenhoofd et al,2000). 
Among the different CaM antagonist commonly used to examine the role of CaM in 
cell functioning, W-7 was chosen in our study as a most suitable CaM inhibitory 
compound, because of its high affinity for CaM and lower cell toxicity compared 
with other CaM antagonists (e.g. phenothiazines). It selectively inhibits the activation 
of CaM targets by binding to its hydrophobic binding pockets. We showed that 
inhibition of CaM with W-7 is associated with a reduction of SMC proliferation and 
partially prevents the large to small phenotypic transition. Our results suggest a 
functional role of CaM in the human atheroma-prone SMC behavior.  
In addition to its major CaM-dependent effects, W-7 shows a weak inhibitory 
potential on different calcium/CaM independent enzymes including protein-kinase C 
(PKC) that could decrease SMC proliferation. However, the concentrations required 
to inhibit PKC are greater than those required to inhibit CaM.  
Although it is widely accepted that calcium/calmodulin-dependent pathways control 
SMC contraction, proliferation, and migration (House et al, 2008; Singer, 2012; Kahl 
& Means, 2003) calmodulin has not previously been considered as a marker of SMC 
subpopulations. Our data in addition might suggest the importance of calcium 
regulation of SMC phenotype. 
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The second aim of this thesis was to further investigate signals, stemming from 
a previous RNA microarray study on large and small SMC populations, in order to 
characterize the expression profiles of SMC subpopulations. Among differentially 
expressed genes our attention focused on NOV. By qPCR we confirmed the higher 
expression of NOV in small as compared to large SMCs. Preliminary results of RNA 
sequencing experiments, conducted by Stefano Volinia of the Ferrara University, and 
by the group of Professor Croce in the University of Columbia, Ohio, further 
validated the differences in NOV expression between small and large populations, 
with higher expression in the atheroma-prone SMC subpopulation. A parallel 
increase in protein expression in small versus large populations was demonstrated in 
this thesis by IF performed on cultured cells. Finding of an increased expression of 
NOV (both at RNA and protein level) in the SMC subpopulation with higher 
proliferative and migration activities suggest that NOV protein could be associated 
with this activities which take part to the atheroma formation. 
The role of NOV in cell proliferation process and in migratory activity is still largely 
debated (Perbal, 2008). Early analysis of CCN3 expression in renal cell carcinoma 
(Glukhova et al. 2001) and prostate cancer cells (Maillard et al. 2001) had led to the 
conclusion that an elevated expression of CCN3 was associated with a high 
proliferative rate for these tumor cells. However evidence accumulated rapidly in 
favor of NOV acting as anti-proliferative  and tumor suppressor but also as a 
metastasis promoter. All these findings clearly produce an apparently paradoxical 
situation. As matter of fact, accumulation of NOV in the nucleus of tumor cells 
(Perbal 1999) is believed to repress the expression of tumor suppressor genes thereby 
contributing to the loss of negative signals controlling proliferation (Planque et al. 
2006). 
Concerning the process of atherosclerotic lesion formation, Shimoyama et al. in 2010 
demonstrated that exogenous NOV inhibited murine smooth muscle cell proliferation 
and knockout mice suffered from enhanced neointimal thickening when challenged 
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with mechanically created vascular injury. This experimental model, that is very 
different from the atherosclerotic process in humans, suggests a protective role of 
NOV with inhibitory activity on proliferation and migration of SMCs.  
Overall the contradictory biological properties observed for NOV may also result 
from the different experimental protocols that were used in the several studies. Indeed 
quite distinct properties of NOV could be explained depending on whether NOV is 
added exogenously or expressed from inside the cells. 
We established by immunohistochemistry that NOV protein is expressed by a large 
number of cells in the plaque and faintly in the media of the vessel. This was also 
confirmed by immunofluorescence which stated that SMCs were positive for NOV. 
Interestingly, NOV interacts with S100A4 (fig. 19), a small calcium binding protein, 
marker of pig rhomboid SMCs and of human atherosclerotic coronary artery SMCs 
(Brisset et al, 2007). We observed that both proteins were more expressed in the 
atheroma prone subpopulation by IF. 
Another member of the CCN family (CCN2) was also examined in this thesis. 
Our interest for CCN proteins is stimulated by their implication in several vascular 
pathologies, including atherosclerosis, restenosis, thrombosis and hypertension. 
 For CCN2 we found a discordant result between cultured SMCs and the tissue 
specimens: in fact higher RNA levels were found in small cell populations whereas 
higher levels of CCN2 were found in NP than in DP portions. The low number of 
observations does not permit us to currently interpret these results. If in fact the 
increased expression of CCN2 in the atheroma prone SMC subpopulation (small 
cells) might be concordant with the generally observation that CCN2 is associated 
with cell proliferation and tumor growth (Perbal, 2008), on the other side it is not 
clear why the grossly normal portion, in which small SMCs are poorly represented, 
showed higher expression levels of CCN2 as compared to the diseased portion. 
Among the signals emerged from the RNA profiling microarray, ENPP2 
showed the highest fold change in expression levels between small and large 
population with a much more expression in atheroprone SMC population.  
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By qPCR we confirmed that ENPP2 mRNA levels were higher in small than in large 
cells and we observed an increased expression of ENNP2 mRNA in DP than in NP 
portions. Data on cells were also confirmed by RNA sequencing (see above as for 
NOV) in the same populations analyzed by microarray. The higher expression of 
ENPP2 in atheroprone SMC populations suggests that ENPP2 could be a component 
of the atherosclerotic process. In this context it is important to remember that ENPP2 
is one of the enzyme able to catalyze the production of lysophosphatidic acid (LPA). 
LPA has a plethora of biological activities on cells of the vessel wall (endothelial 
cells, smooth muscle cells, macrophages) that are all key players in atherosclerotic 
and atherothrombotic processes (Schober & Siess, 2012).  After local formation in 
response to danger signals such as those initiated by vascular injury or inﬂammation 
LPA rapidly activates cells in the immediate vicinity (Tokumura, 1995).  
Some of the effects of LPA appear to be mediated by the activation of the nuclear 
receptor PPARg, specifically in macrophages and SMCs (McIntyre et al, 2003; 
Zhang et al, 2004). LPA potently stimulates the proliferation of cultured SMCs and 
most probably contributes to ox-LDL-induced SMC proliferation (Tokumura et al, 
1994; Natarajan et al, 1995; Kim et al, 2006; Damirin et al, 2007; Komachi et al, 
2009). Furthermore, LPA induces the pro-atherogenic factors CCL2 (MCP-1) and IL-
6 in human vascular SMCs in vitro (Kaneyuki et a., 2007; Hao et al, 2010).  
It is noteworthy that from a recent GWAS study for general cancer risk loci in the 
entire region of 8q24, emerged that NOV and ENPP2 could be functionally related to 
cancer susceptibility via cis-regulation of NOV and/or ENPP2 (Abra et al, 2011). 
A complex regulatory network involving 8q24 proto-oncogene c-MYC could be 
functionally link these two proteins (Nikolsky et al, 2005). 
 
Conclusions   
 
This study shows that large and small SMC subpopulations with different 
phenotypes can be isolated form CEA. Characterization of both subpopulations 
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indicates that small SMCs exhibit "atheroma-prone" phenotype, characterized by high 
proliferation and low level of differentiation. 
We show that small SMCs, overexpressing CaM, proliferate more actively than large 
SMCs. Coculture of large SMCs with plaque-derived macrophages or conditioned 
medium or plaque induced a transition to the small phenotype with increased CaM 
expression. The CaM inhibitor W-7 decreased the proliferation of small SMCs and  
partially prevented the large to small phenotypic transition. 
Analysis of the expression profiles in SMC subpopulations and in carotid tissue 
specimens showed differences which point to NOV and ENPP2 as components of the 
atheroprone phenotype.  
Additional studies in a larger number of samples, both at RNA and protein 
levels in cells and in tissue are needed to confirm data obtained. Moreover 
experiments addressing functional implications would required to corroborate the 
suggested association of markers, like CaM, NOV and ENPP2, with the 
atherosclerotic process.  
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